inVentiv Group Holdings

General Information

We are a leading global provider of outsourced clinical development and commercialization services to biopharmaceutical companies. We are the only provider delivering a full suite of services to enhance our clients’ ability to successfully develop, launch and market their products. We offer our services on both a standalone basis and as integrated solutions to support clinical development and commercialization. Our solutions are designed to drive greater efficiency and lower costs. We helped develop or commercialize over 80% of all new molecular entities approved by the FDA and 70% of those approved by the EMA over the last five years through our innovative model. In 2015, we served more than 550 client organizations, including all 20 of the largest global biopharmaceutical companies, and have the ability to service clients in over 90 countries.

Employees: 14000
Founded: 2010
Contact Information
Address 1 Van De Graaff Drive, Burlington, MA 01803, US
Phone Number (800) 416-0555
Web Address
View Prospectus: inVentiv Group Holdings
Financial Information
Market Cap
Revenues $2435.3 mil (last 12 months)
Net Income $-125.5 mil (last 12 months)
IPO Profile
Symbol IVH
Exchange NYSE
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Credit Suisse/ Morgan Stanley/ Goldman Sachs/ Jefferies
CO-Managers Citigroup/ BofA Merrill Lynch/ Barclays/ Wells Fargo Securities/ Baird/ William Blair
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change